Long-Term Stock Portfolio: 15 Best Stocks for 20 Years

8. CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its financial results for 2025, highlighting a period of significant commercial and clinical growth. The company’s flagship gene-editing therapy, CASGEVY, generated $116 million in total revenue for the year, with $54 million occurring in Q4 alone. This growth was driven by a nearly threefold increase in patient initiations compared to the previous year. To date, 147 patients have started the treatment process for sickle cell disease or beta thalassemia, supported by expanded reimbursement access across the US, Europe, and the Middle East.

Beyond its commercial success, the company is advancing a diverse ‘in vivo’ liver editing portfolio that delivers treatments directly to the body using lipid nanoparticles/LNP. Key programs include CTX310 for cardiovascular conditions and the upcoming CTX460 for alpha-1 antitrypsin deficiency, which is expected to enter clinical trials in mid-2026.

CRISPR is expanding its reach through a collaboration with Sirius Therapeutics on siRNA-based programs targeting thromboembolic diseases. These therapies represent a multi-billion-dollar opportunity, with Phase 2 data for their lead Factor XI candidate expected in H2 2026. The company’s clinical pipeline continues to mature with ‘zugo-cel,’ which is a CAR-T cell therapy being tested for both autoimmune diseases like lupus and various B-cell cancers. CRISPR Therapeutics (NASDAQ:CRSP) is also making strides in regenerative medicine with CTX213, an islet cell replacement candidate for Type 1 diabetes that has shown promising preclinical efficacy.

CRISPR Therapeutics (NASDAQ:CRSP) is a gene editing company that develops gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (Cas9) platform.